| ID | 119177 |
| 著者 |
板東, 浩
Tokushima University|Medical Research|Japan Low Carbohydrate Diet Promotion Association|Yoshinogawa Hospital
KAKEN研究者をさがす
Ogawa, H
Yoshinogawa Hospital
Kobayashi, H
Yoshinogawa Hospital
Nakanishi, S
Yoshinogawa Hospital
Watanabe, O
Yoshinogawa Hospital
|
| キーワード | Imeglimin (Twymeeg)
Glubes (mitiglinide/voglibose)
EquMet (Vildagliptin/Metformin)
Trials of IMeglimin for Efficacy and Safety (TIMES)
Oral hypoglycemic agent (OHA)
|
| 資料タイプ |
学術雑誌論文
|
| 抄録 | For latest topic, imeglimin (Twymeeg) shows clinical efficacy among several oral hypoglycemic agents (OHAs). The case is 79-year-old male with Type 2 diabetes (T2D) for long. He had hypoglycemic episode in Sept 2022, and then Glubes (mitiglinide/voglibose) was discontinued and EquMet (Vildagliptin/Metformin) was started in Oct 2022. His HbA1c increased to 8.3% in Jan 2023, followed by initiating Twymeeg. Clinical efficacy showed satisfactory degree for glucose variability as 7.3% for 8 weeks. He has body mass index (BMI) 22.0 kg/m2, and daily exercise habit. These factors may contribute diabetic improvement in addition to clinical efficacy of EquMet and Twymeeg.
|
| 掲載誌名 |
SunText Review of Endocrine Care
|
| ISSN | 27715469
|
| 出版者 | SunText Reviews
|
| 巻 | 2
|
| 号 | 1
|
| 開始ページ | 109
|
| 発行日 | 2023-03-21
|
| 権利情報 | This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
|
| 出版社版DOI | |
| 出版社版URL | |
| フルテキストファイル | |
| 言語 |
eng
|
| 著者版フラグ |
出版社版
|
| 部局 |
医学系
病院
|
